



Corp. Off.:- 201, "The Summit Business Bay"
Behind Guru Nanak Petrol Pump,
Off Andheri Kurla Road, Andheri (E),
Mumbai - 400 093 (India)
Ph. : +91 22 69073100



9th November, 2023

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai-400001

Kind Attn: General Manager-DCS

Scrip Code: **533543**

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G

Bandra Kurla Complex

Bandra (E), Mumbai-400051

Kind Attn: Head- Listing

Symbol: **BROOKS**

Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Standalone and Consolidated Financial Results of the Company for the 2nd quarter and half yearly ended 30th September, 2023. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow Statement as at 30.09.2023 together with the Limited Review Report are attached.

The Board meeting commenced at 2:30 pm (IST) and concluded at 3:40 pm (IST).

This is for your information and record.

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

Jai Vaidya

Company Secretary cum Compliance Officer

Encl.: As Stated above

Statements of unaudited Financial Results for the Quarter Ended 30th September 2023

(Rs. In Lakhs)

Particulars	Standalone						Consolidated					
	Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
	30-Sep-23	30-Jun-23	30-Sep-22	30-Sep-23	30-Sep-22	31-Mar-23	30-Sep-23	30-Jun-23	30-Sep-22	30-Sep-23	30-Sep-22	31-Mar-23
	Unaudited			Unaudited		Audited	Unaudited			Unaudited		Audited
1 Income												
Revenue from operations	2,431.51	1,570.27	1,589.49	4,001.78	3,083.77	5,553.80	2,431.51	1,570.27	1,808.09	4,001.78	3,520.45	6,320.46
Other Income	9.21	5.48	6.51	14.69	11.13	10.72	9.21	5.48	13.70	14.69	17.11	20.34
Total income	2,440.72	1,575.75	1,596.00	4,016.47	3,094.90	5,564.52	2,440.72	1,575.75	1,821.79	4,016.47	3,537.56	6,340.80
2 Expenses												
(a) Cost of materials consumed	1,222.97	1,066.54	835.73	2,289.51	1,670.35	3,232.84	1,222.97	1,066.54	2,116.56	2,289.51	3,566.22	4,154.53
(b) Purchase of Stock in Trade	362.69	86.09	191.01	448.78	470.10	611.99	362.69	86.09	86.48	448.78	365.57	487.24
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	160.37	(54.55)	87.19	105.82	223.88	200.90	160.37	(54.55)	(729.36)	105.82	(842.21)	418.45
(d) Employees benefits expenses	265.21	277.35	279.93	542.56	634.92	1,154.12	265.21	277.35	522.35	542.56	1,093.51	1,734.16
(e) Finance Costs	18.67	17.11	18.51	35.78	34.22	76.67	18.67	17.11	62.83	35.78	125.13	218.32
(f) Depreciation and amortization expenses	44.13	44.09	42.95	88.22	85.29	171.74	44.13	44.09	227.99	88.22	426.20	702.68
(g) Other expenses	248.65	192.39	222.57	441.04	515.03	935.38	248.65	192.39	734.59	441.04	1,119.81	2,167.91
Total Expenses	2,322.69	1,629.02	1,677.89	3,951.71	3,633.79	6,383.64	2,322.69	1,629.02	3,021.44	3,951.71	5,854.23	9,883.29
3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax	118.03	(53.27)	(81.89)	64.76	(538.89)	(819.12)	118.03	(53.27)	(1,199.65)	64.76	(2,316.67)	(3,542.50)
4 Share of Profit / (Loss) from Jointly controlled entities and associates	-	-	-	-	-	-	(281.75)	(393.76)	26.51	(675.51)	26.51	(331.00)
Profit/(Loss) before Exceptional item and tax	118.03	(53.27)	(81.89)	64.76	(538.89)	(819.12)	(163.71)	(447.03)	(1,173.14)	(610.75)	(2,290.16)	(3,873.49)
5 Exceptional items	-	-	-	-	-	-	-	-	-	-	-	(35.67)
6 Profit/(Loss) from ordinary activities before tax	118.03	(53.27)	(81.89)	64.76	(538.89)	(819.12)	(163.71)	(447.03)	(1,173.14)	(610.75)	(2,290.16)	(3,837.82)
7 Tax Expense:												
Deferred Tax Liability / (Assets)(Refer note 7)	-	-	-	-	-	-	-	-	(385.48)	-	(562.73)	(732.40)
MAT credit reversal	-	-	-	-	-	-	-	-	-	-	-	-
Tax of earlier years	-	-	-	-	-	-	-	-	-	-	-	-
8 Net Profit/(loss) after tax	118.03	(53.27)	(81.89)	64.76	(538.89)	(819.12)	(163.71)	(447.03)	(787.66)	(610.75)	(1,727.43)	(3,105.42)
9 Other Comprehensive Income												
Items That will not be reclassified into Profit or loss												
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	-	-	-	-	-	(4.10)	-	-	-	-	-	(4.10)
Gain on remeasuring FVTPL financial assets	-	-	-	-	-	0.81	-	-	-	-	-	0.81
10 Total Comprehensive income for the period	118.03	(53.27)	(81.89)	64.76	(538.89)	(822.41)	(163.71)	(447.03)	(787.66)	(610.75)	(1,727.43)	(3,108.71)
Net Profit attributable to												
Owners of equity	-	-	-	-	-	-	-	-	(466.20)	-	(1,158.26)	(2,090.01)
Non Controlling Interest	-	-	-	-	-	-	-	-	(319.48)	-	(569.17)	(1,015.41)
Other Comprehensive Income attributable to :												
Owners of equity	-	-	-	-	-	-	-	-	-	-	-	(3.29)
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-
Total Comprehensive Income attributable to												
Owners of Equity	-	-	-	-	-	-	-	-	(466.20)	-	(1,158.26)	(2,093.30)
Non Controlling Interest	-	-	-	-	-	-	-	-	(319.48)	-	(569.17)	(1,015.41)
11 Paid-up equity share capital (Face Value of Rs. 10 each)	2,624.67	2,470.28	2,470.28	2,624.67	2,470.28	2,470.28	2,624.67	2,470.28	2,470.28	2,624.67	2,470.28	2,470.28
12 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year.	3,207.61	3,207.61	4,030.03	3,207.61	4,030.03	4,030.03	4,925.05	4,925.05	6,278.73	4,925.05	6,278.72	6,278.73
13 Earnings per share (of Rs. 10/- each)												
(not annualised)												
(a) Basic	0.46	(0.22)	(0.33)	0.25	(2.18)	(3.32)	(0.64)	(1.81)	(3.19)	(2.38)	(6.99)	(12.57)
(b) Diluted	0.46	(0.22)	(0.33)	0.25	(2.18)	(3.32)	(0.64)	(1.81)	(3.19)	(2.38)	(6.99)	(12.57)


Notes:

- The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on 09th November 2023
- The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- The Board of Directors at its meeting held on July 18, 2023, has inter alia considered and approved the rights issue of 15,43,926 fully paid-up Equity Shares of Rights issue price of Rs.75 per equity share [including a premium of Rs. 65 per Equity Share] for amount aggregating up to Rs. 1,157.94 lakhs. Subsequently, Rights Issue Letter of Offer (LoF) was filed on August 1, 2023 with BSE Limited (BSE), August 2, 2023 with National Stock Exchange of India Limited (NSE) and August 3, 2023 with Securities and Exchange Board of India (SEBI). The company has allotted the shares on 28th August 2023. The Right Issue proceeds were fully utilised for objects mentioned in Letter of offer dated July 18, 2023.
- The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- During the Quarter Ended December 31, 2022 the company has lost control over its own subsidiary company Brooks Steriscience Limited (BSL) and the company now jointly controls the entity along with its JV partner and has accounted accordingly subsequent to loss of control. Hence the current year quarter figures are not comparable with previous year quarter figures.
- In the absence of future taxable profit, The Company has not recognised deferred tax asset on its business losses/depreciation in accordance with Ind AS 12 "Income taxes"
- The Company operates in one reportable business segment i.e "Pharmaceuticals".
- Figures of the previous reporting period has been reclassified/ regrouped wherever necessary to correspond with the figures of the current reporting period.

For and on Behalf of the Board

Jitendra Pratap Rambahadur Singh

JITENDRAPRATAP RAMBAHADUR SINGH
 Din : 09796568
 Wholetime Director



Place : Baddi
 Date : 09th November 2023

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No :+91 1795 236939

Statement of Assets & Liabilities as at 30th September, 2023

(Rs. In Lakhs)

Particulars	Standalone		Consolidated	
	As at September 30, 2023 (unaudited)	As at March 31, 2023 (Audited)	As at September 30, 2023 (unaudited)	As at March 31, 2023 (Audited)
A ASSETS				
1 Non Current Assets				
(a) Property, Plant and Equipment	1,341.13	1,401.53	1,341.13	1,401.53
(b) Capital work in progress	-	-	-	-
(c) Right to use Assets	66.02	79.36	66.02	79.36
(d) Intangible asset	13.62	19.88	13.62	19.88
(e) Intangible asset under Development	-	-	-	-
(f) Financial Assets				
(i) Investments	4,780.16	4,685.16	5,822.08	6,402.60
(ii) Security deposits	51.77	31.57	51.77	31.57
(ii) Other Financial Assets	12.99	16.85	12.99	16.85
(g) Income Tax Assets (Net)	249.97	247.31	249.97	247.31
(h) Deferred tax asset (net)	-	-	-	-
(i) Other Non Current Assets	-	-	-	-
Total Non - Current Assets	6,515.66	6,481.66	7,557.58	8,199.10
2 Current assets				
(a) Inventories	1,024.03	1,130.32	1,024.03	1,130.32
(b) Financial Assets				
(i) Trade receivables	1,574.64	1,275.43	1,574.64	1,275.42
(ii) Security Deposit	-	-	-	-
(iii) Cash and Cash Equivalents	19.73	2.32	19.73	2.32
(iv) Bank Balances other than cash & cash equivalents	30.59	105.21	30.59	105.21
(v) Other Financial Assets	49.88	30.29	49.88	30.29
(c) Other Current Assets	342.70	217.06	342.70	217.07
Total Current Assets	3,041.57	2,760.63	3,041.57	2,760.63
TOTAL ASSETS	9,557.23	9,242.29	10,599.15	10,959.73
B EQUITY AND LIABILITIES				
1 Equity				
(a) Equity Share Capital	2,624.67	2,470.28	2,624.67	2,470.28
(b) Other Equity	4,245.15	3,207.61	5,287.07	4,925.05
Equity attributable to Owners of the Company	6,869.82	5,677.89	7,911.74	7,395.33
Non-Controlling interests	-	-	-	-
Total Equity	6,869.82	5,677.89	7,911.74	7,395.33
Liabilities				
2 Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	-	-	-	-
(ii) Lease Liability	46.74	60.22	46.74	60.22
(iii) Other Financial Liabilities	131.32	55.93	131.32	55.93
(b) Provisions	73.22	146.12	73.22	146.12
Total Non - Current Liabilities	251.28	262.27	251.28	262.27
3 Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	348.18	566.35	348.18	566.35
(ii) Lease liability	25.87	24.65	25.87	24.65
(iii) Trade Payables				
- Due to micro and small enterprises	768.45	871.15	768.45	871.15
- Due to Others	905.24	1,465.89	905.24	1,465.89
(iv) Other Financial Liabilities	126.98	127.85	126.98	127.85
(b) Other current liabilities	165.55	114.44	165.55	114.44
(c) Provisions	95.86	131.80	95.86	131.80
Total Current Liabilities	2,436.13	3,302.13	2,436.13	3,302.13
TOTAL EQUITY AND LIABILITIES	9,557.23	9,242.29	10,599.15	10,959.73

For Brooks Laboratories Limited



JITENDRAPRATAP RAMBAHADUR SINGH

Din : 09796568

Wholetime Director

Place : Baddi
Date : 09th November 2023

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net | Telefax No :+91 1795 236939

Cash Flow Statement for the period ended 30th September, 2023

(Rs. In Lakhs)

Particulars	Standalone		Consolidated	
	Year ended 30th September 2023	Year ended 31 March 2023	Year ended 30th September 2023	Year ended 31 March 2023
	Unaudited	Audited	Unaudited	Audited
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net (loss) / profit before tax	64.76	(819.11)	64.76	(3,542.51)
Adjustments for				
Depreciation and amortisation expense	88.22	171.74	88.22	702.68
Finance cost	35.78	76.67	35.78	218.32
Interest income	(3.66)	(7.22)	(3.66)	(9.21)
Remeasurement of Defined benefit obligations	-	(4.10)	-	(4.10)
Dividend from current investments	(0.40)	(0.40)	(0.40)	(0.40)
Liability no longer payable	(0.38)	-	(0.38)	19.06
Provision for Expected credit loss	10.00	38.64	10.00	38.64
Unrealised Foreign Exchange Gain	(3.79)	0.05	(3.79)	0.05
Operating profit before working capital changes	190.53	(543.75)	190.53	(2,577.47)
Adjustments for changes in working capital:				
Decrease / (increase) in Trade Receivables	(309.22)	189.43	(309.22)	(268.73)
Decrease / (increase) in Inventories	106.32	528.44	106.32	328.60
Decrease / (increase) in Other Assets	(125.65)	82.68	(125.65)	(227.80)
Decrease / (increase) in Other Financial Assets	(39.80)	153.77	(39.80)	134.53
(Decrease) / Increase in Trade and Other Payables	(659.19)	(237.70)	(659.19)	1,083.78
(Decrease) / Increase in Other Financial Liabilities	(20.46)	(32.99)	(20.46)	(37.45)
(Decrease) / Increase in Other Liabilities	51.12	(103.50)	51.12	47.29
(Decrease) / Increase in Provisions	(108.84)	39.13	(108.84)	83.46
Cash generated from / (used in) operations	(915.19)	75.49	(915.19)	(1,433.80)
Direct taxes paid (net of refunds received)	(2.66)	(19.27)	(2.66)	(15.26)
Net cash (used in) / from generated from operating activities	(917.85)	56.22	(917.85)	(1,449.06)
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of property, plant and equipment (including capital work in progress and capital advances)	(8.21)	(46.75)	(8.21)	(46.75)
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	78.45	(0.84)	78.45	86.62
Interest received	3.66	7.22	3.66	9.21
Dividend received	0.40	0.40	0.40	0.40
Net cash (used in) / generated from investing activities	74.30	(39.97)	74.30	49.48
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds by Minority Interest	-	-	-	1,762.94
Proceeds/ (Repayment) from borrowings (net)	(218.17)	74.06	(218.17)	(383.52)
Proceeds from Issue of Equity Shares	1,127.17	-	1,127.17	-
Repayment of Lease Liabilities	(12.26)	(19.70)	(12.26)	(19.70)
Finance costs paid	(35.78)	(76.67)	(35.78)	(218.32)
Net cash (used in) / from financing activities	860.96	(22.31)	860.96	1,141.40
Net increase / (decrease) in cash and cash equivalents	17.41	(6.05)	17.41	(258.18)
Cash and cash equivalents at the beginning of the year	2.32	8.38	2.32	260.50
Cash and cash equivalents at the end of the year	19.73	2.32	19.73	2.32


For and on Behalf of Board



JITENDRAPRATAP RAMBAHADUR SINGH

Din : 09795568

Wholetime Director



Place : Baddi

Date : 09th November 2023

SGCO & Co.LLP

Chartered Accountants

Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the quarter and half year ended on September 30, 2023, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To,
The Board of Directors of
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Brooks Laboratories Limited (The "Company"), for the quarter and half year ended on September 30, 2023. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S G C O & Co. LLP
Chartered Accountants
Firm's Registration No. 112081W/W100184


Suresh Murarka
Partner
Mem. No. 044739
UDIN: 23044739BGUNZR5178
Place: Mumbai
Date: 09th November 2023



4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail. info@sgco.co.in
www.sgco.co.in

SGCO & Co.LLP

Chartered Accountants

Limited Review Report on Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2023, of Brooks Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Brooks Laboratories Limited** ("the Parent") and its Jointly controlled entity and associate for the quarter and half year ended September 30, 2023 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
- Brooks Laboratories Limited (Parent Company)
 - Brooks Steriscience Limited (Jointly Controlled Entity)
 - Steribrooks Penems Private Limited (Associate Company)



4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail. info@sgco.co.in
www.sgco.co.in

SGCO & Co. LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of one Jointly Controlled Entity vis Brooks Steriscience Limited included in the consolidated unaudited financial results, whose financial statement include the Group share of net loss of Rs. 281.75 Lakhs and 671.51 lakhs for the quarter and half year ended 30th September 2023 respectively, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Jointly controlled entity, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

The consolidated financial statements also includes the Group's share is NIL for the quarter and half year ended September 30, 2023, as considered in the consolidated unaudited financial statements, in respect of one associate Steribrooks Penems Private Limited whose financial statement/ financial information/ financial results have not been limited reviewed and have been furnished to us by the Management.

Our conclusion on the Statement is not modified in respect of the above matters.

For S G C O & Co. LLP

Chartered Accountants

Firm Registration No. 112081W/W100184


Suresh Murarka

Partner

Mem.No. 044739

UDIN: 23044739BGUNZS2183

Place: Mumbai

Date: 09th November 2023

